US Bancorp’s Cellectar Biosciences CLRB Stock Holding History

US Bancorp’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8	Hold	3	–	–	﹤0.01%	4149
2026 Q1	$8	Hold	3	–	–	﹤0.01%	4157
2025 Q4	$9	Hold	3	–	–	﹤0.01%	4024
2025 Q3	$17	Hold	3	–	–	﹤0.01%	3988
2025 Q2	$21	Hold	3	–	–	﹤0.01%	4139
2025 Q1	$32	Sell	3 -10	-77%	-$91	﹤0.01%	4159
2024 Q4	$115	Hold	13	–	–	﹤0.01%	4105
2024 Q3	$824	Hold	13	–	–	﹤0.01%	3915
2024 Q2	$963	Buy	13 +3	+30%	+$288	﹤0.01%	3815
2024 Q1	$1.13K	Hold	10	–	–	﹤0.01%	3802
2023 Q4	$789	Hold	10	–	–	﹤0.01%	3820
2023 Q3	$752	Hold	10	–	–	﹤0.01%	3809
2023 Q2	$556	Hold	10	–	–	﹤0.01%	3869
2023 Q1	$408	Hold	10	–	–	﹤0.01%	3978
2022 Q4	$487	Hold	10	–	–	﹤0.01%	4003
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	3925
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	3933
2022 Q1	$2K	Hold	10	–	–	﹤0.01%	3806
2021 Q4	$2K	Hold	10	–	–	﹤0.01%	3870
2021 Q3	$3K	Hold	10	–	–	﹤0.01%	3767
2021 Q2	$3K	Hold	10	–	–	﹤0.01%	3716
2021 Q1	$5K	Hold	10	–	–	﹤0.01%	3483
2020 Q4	$6K	Hold	10	–	–	﹤0.01%	3338
2020 Q3	$4K	Hold	10	–	–	﹤0.01%	3343
2020 Q2	$4K	Hold	10	–	–	﹤0.01%	3366
2020 Q1	$4K	Hold	10	–	–	﹤0.01%	3301
2019 Q4	$6K	Hold	10	–	–	﹤0.01%	3221
2019 Q3	$6K	Hold	10	–	–	﹤0.01%	3186
2019 Q2	$6K	Hold	10	–	–	﹤0.01%	3226
2019 Q1	$7K	Hold	10	–	–	﹤0.01%	3145
2018 Q4	$4K	Hold	10	–	–	﹤0.01%	3254
2018 Q3	$9K	Hold	10	–	–	﹤0.01%	3145
2018 Q2	$18K	Hold	10	–	–	﹤0.01%	2967
2018 Q1	$32K	Hold	10	–	–	﹤0.01%	2796
2017 Q4	$39K	Hold	10	–	–	﹤0.01%	2703
2017 Q3	$48K	Buy	+10	New	+$48.5K	﹤0.01%	2587
2017 Q2	–	Hold	0	–	–	–	3540
2017 Q1	–	Hold	0	–	–	–	3554
2016 Q4	–	Hold	0	–	–	–	3436
2016 Q3	–	Hold	0	–	–	–	3528
2016 Q2	–	Hold	0	–	–	–	3550
2016 Q1	–	Hold	0	–	–	–	3539
2015 Q4	–	Hold	0	–	–	–	3612
2015 Q3	–	Hold	0	–	–	–	3587
2015 Q2	–	Hold	0	–	–	–	3565
2015 Q1	–	Hold	0	–	–	–	3565
2014 Q4	–	Hold	0	–	–	–	3536
2014 Q3	–	Hold	0	–	–	–	3504

Other funds holding CLRB

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

RCA

Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

US Bancorp's CLRB Position: Q2 2026 in Review

US Bancorp held its Cellectar Biosciences (CLRB) position steady in Q2 2026 at 3 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #4149.

US Bancorp first reported a position in CLRB in Q3 2017 and has held it in 36 quarters since. The position peaked at $48K in Q3 2017. 18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

US Bancorp held 3 shares of Cellectar Biosciences worth $8 as of Q2 2026.
US Bancorp left its Cellectar Biosciences share count unchanged in Q2 2026.
Cellectar Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4149 holding.
US Bancorp first reported a position in Cellectar Biosciences in Q3 2017 and has held it in 36 quarters since.
US Bancorp's Cellectar Biosciences position peaked at $48K in Q3 2017.
18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.